Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.

Traynor, Anne M; Thomas, James P; Ramanathan, Ramesh K; Mody, Tarak D; Alberti, Dona; Wilding, George; Bailey, Howard H

Traynor, Anne M; Thomas, James P; Ramanathan, Ramesh K; Mody, Tarak D; Alberti, Dona; Wilding, George; Bailey, Howard H.

Affiliation

Traynor AM; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI 53792, USA. amt@medicine.wisc.edu

Invest New Drugs ; 29(2): 316-22, 2011 Apr.

Article in En | MEDLINE | ID: mdl-19997959

Subject(s)

Antineoplastic Agents/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Doxorubicin/therapeutic use; Metalloporphyrins/therapeutic use; Neoplasms/drug therapy; Adult; Aged; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/adverse effects; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Demography; Dose-Response Relationship, Drug; Doxorubicin/administration & dosage; Doxorubicin/adverse effects; Female; Humans; Male; Metalloporphyrins/administration & dosage; Metalloporphyrins/adverse effects; Middle Aged; Neoplasms/pathology; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Doxorubicin / Metalloporphyrins / Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2011 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google